DPP-4 inhibitors

Best Practice and Research in Clinical Endocrinology and Metabolism

Volumn 21, Issue 4, 2007, Pages 517-533

  Ahrén, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

dipeptidyl peptidase 4; glucagon like peptide 1; sitagliptin; treatment; type 2 diabetes; vildagliptin

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ALOGLIPTIN; ALS 2 0426; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GRC 8200; HEMOGLOBIN A1C; INSULIN; METFORMIN; PHX 1149; PIOGLITAZONE; PLACEBO; PSN 9301; R 1438; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SSR 162369; SYR 619; TA 6666; TS 021; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE PYRROLIDIDE; VILDAGLIPTIN;

ADD ON THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIABETES CONTROL; DIABETOGENESIS; DIET THERAPY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ECG ABNORMALITY; ENZYME INHIBITION; ENZYME SPECIFICITY; EXERCISE; GLUCAGON RELEASE; HEMOGLOBIN BLOOD LEVEL; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; MAXIMUM PLASMA CONCENTRATION; METABOLIC REGULATION; MONOTHERAPY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADAMANTANE; ANIMALS; ANTIGENS, CD26; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LIPID METABOLISM; METFORMIN; NITRILES; PROTEASE INHIBITORS; PYRAZINES; PYRROLIDINES; SUBSTRATE SPECIFICITY; THIAZOLIDINEDIONES; TRIAZOLES;

EID: 36549009003     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2007.07.005     Document Type: Review

References (75)

1. Elrick H., Stimmler L., Hlad C.J., et al. Plasma insulin response to oral and intravenous glucose administration. The Journal of Clinical Endocrinology and Metabolism 24 (1964) 1076-1082
2. Drucker D.J. The biology of incretin hormones. Cell Metabolism 3 (2006) 153-165
3. Nauck M., Stöckmann F., Ebert R., et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1986) 46-54
4. Vilsboll T., and Holst J.J. Incretins, insulin secretion and type-2 diabetes mellitus. Diabetologia 47 (2004) 357-366
5. Holst J.J., and Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. American Journal of Physiology 287 (2004) E199-E206
6. Deacon C.F. What do we know about the secretion and degradation of incretin hormones?. Regulatory Peptides 128 (2006) 117-124
7. Deacon C.F. Circulation and degradation of GIP and GLP-1. Hormone and Metabolic Research 36 (2004) 761-765
8. Holz G. New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic β-cells. Hormone and Metabolic Research 36 (2004) 787-794
9. Xu G., Stoffers D.A., Habener J.F., et al. Exendin 4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
10. Farilla L., Hui H., Bertolotto C., et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 (2002) 4397-4408
11. Perfetti R., and Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Hormone and Metabolic Research 36 (2004) 804-810
12. Stoffers D.A., Kieffer T.J., Hussain M.A., et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49 (2000) 741-748
13. Meier J.J., Gallwitz B., Siepmann N., et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycemia. Diabetologia 46 (2003) 798-801
14. Nauck M.A., Kleine N., Ørskov C., et al. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 (1993) 741-744
15. Nakabayashi H., Nishizawa M., Nakagawa A., et al. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. American Journal of Physiology 271 (1996) E808-E813
16. Balkan B., and Liu X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. American Journal of Physiology 279 (2000) R1449-R1454
17. Ahrén B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. American Journal of Physiology 286 (2004) R269-R272
18. Nikolaidis L.A., Mankad S., Sokos G.G., et al. Effects of glucagon-like peptide-1 in patients with myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004) 962-965
19. Nyström T., Gutniak M., Zhang Q., et al. Effects of glucagon-like peptide-1 on endothelial function in type-2 diabetes patients with stable coronary artery disease. American Journal of Physiology 287 (2004) E1209-E1215
20. Gutniak M., Ørskov C., Holst J.J., et al. Antidiabetic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. The New England Journal of Medicine 326 (1992) 1316-1322
21. Nauck M.A., Wollschlager D., Werner J., et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1[7-36 amide]) in patients with NIDDM. Diabetologia 39 (1996) 1546-1553
22. Zander M., Madsbad S., Madsen J.L., et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type-2 diabetes: a parallel-group study. Lancet 359 (2002) 824-830
23. Ahrén B. Exenatide: a novel treatment of type-2 diabetes. Therapy 2 (2005) 207-222
24. Drucker D.J. Biologic actions and therapeutical potential of the proglucagon-derived peptides. Nature Clinical Practice 1 (2005) 22-31
25. Holst J.J. Glucagon-like ptpide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 49 (2006) 253-260
26. Ahrén B. Inhibition of dipeptidyl peptidase-4 (DPP-4) - a novel approach to treat type-2 diabetes. Current Enzyme Inhibition 1 (2005) 65-73
27. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type-2 diabetes. Lancet 368 (2006) 1696-1705
28. Barnett A. DPP-4 inhibitors and their potential role in the management of type-2 diabetes. International Journal of Clinical Practice 60 (2006) 1454-1470
29. Meier J.J., and Nauck M.A. GIP as a potential therapeutic agent?. Hormone and Metabolic Research 36 (2004) 859-866
30. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regulatory Peptides 85 (1999) 9-24
31. Lambeir A.M., Durinx C., Sharpe S., et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Critical Reviews In Clinical Laboratory Sciences 40 (2003) 209-294
32. Marguet D., Baggio L., Kobayashi T., et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proceedings of the National Academy of Sciences of the United States of America 97 (2000) 6874-6879
33. Holst J.J., and Deacon C.F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type-2 diabetes. Diabetes 47 (1998) 1663-1670
34. Deacon C.F., Hughes T.E., and Holst J.J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in anesthetized pigs. Diabetes 47 (1998) 764-769
35. Ahrén B., Holst J.J., Mårtensson H., et al. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. European Journal of Endocrinology 404 (2000) 239-245
36. Ahrén B., Landin-Olsson M., Jansson P.A., et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type-2 diabetes. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 2078-2084
37. Villhauer E.B., Brinkman J.A., Naderi G.B., et al. 1[[(3-hydroxy-1-adamantyl)amino-]acetyl]-2-cyano-(s)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. Journal of Medicinal Chemistry 46 (2003) 2774-2789
38. Kim D., Wang L., Beconi M., et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazol[4,3,a]pyrazi n-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type-2 diabetes. Journal of Medicinal Chemistry 48 (2005) 141-151
39. He Y.L., Balch A., and Campestrini J. Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type-2 diabetes. Clinical Pharmacology and Therapy 56 (2005) 19
40. Herman G.A., Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clinical Pharmacology and Therapy 78 (2005) 675-688
41. Bergman A.J., Coyte J., and Yi B. Effect of renal insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor. Clinical Pharmacology and Therapy 38 (2006) [abstr 46]
42. Herman G.A., Bergman A., Stevens C., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type-2 diabetes. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 4612-4619
43. Burkey B.E., Li X., Bolognese K.L., et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. The Journal of Pharmacology and Experimental Therapy 315 (2005) 688-695
44. Mika M., Stashko M., Lubben T., et al. Acute DPP IV inhibition minimizes glucose and insulin response to a glucose challenge in a diabetic mouse. Diabetes 52 Suppl 1 (2003) A350
45. Sörhede Winzell M., and Ahrén B. The high-fat fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type-2 diabetes. Diabetes 53 Suppl 3 (2003) S215-S219
46. Mu J., Woods J., Zhou Y.P., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type-2 diabetes. Diabetes 55 (2006) 1695-1704
47. Ahrén B., Simonsson E., Larsson H., et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type-2 diabetes. Diabetes Care 25 (2002) 869-875
48. Ristic S., Byiers S., Foley J., et al. Improved glucaemic control with dipeptidyl peptidase-4 inhibition in patients with type-2 diabetes: vildagliptin (LAF237) dose response. Diabetes, Obesity & Metabolism 7 (2005) 692-698
49. Pratley R.E., Jauffret-Kamel S., Galbreath E., et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type-2 diabetes. Hormone and Metabolic Research 387 (2006) 423-438
50. Pi-Sunyer F.X., Schweizer A., Mills D., et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type-2 diabetes. Diabetes Research and Clinical Practice 76 (2007) 132-138
51. Rosenstock J., Baron M.A., Dejager S., et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type-2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30 (2007) 217-223
52. Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine, in press.
53. Hanefeld M., Herman G., Mickel C., et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type-2 diabetes. Diabetologia 49 Suppl 1 (2005) A287
54. Scott R., Wu L., Sanchez M., et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type-2 diabetes. International Journal of Clinical Practice 61 (2007) 171-180
55. Raz I., Hanefeld M., Xu L., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type-2 diabetes mellitus. Diabetologia 49 (2006) 2564-2571
56. Aschner P., Kipnes M.S., Lunceford J.K., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type-2 diabetes. Diabetes Care 29 (2006) 2632-2637
57. Ahrén B., Gomis R., Standl E., et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type-2 diabetes. Diabetes Care 27 (2004) 2874-2880
58. Bosi E., Camisaca R.P., Collober C., et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type-2 diabetes inadequately controlled with metformin. Diabetes Care 30 (2007) 890-895
59. Charbonnel B., Karasik A., Liu J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type-2 diabetes inadequately controlled with metformin alone. Diabetes Care 29 (2006) 2638-2643
60. Nauck M.A., Meininger G., Sheng D., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity & Metabolism 9 (2007) 194-205
61. Garber A.J., Schweizer A., Baron M.A., et al. Vildagliptin in combination with pioglitazeone improves glycaemic control in patients with type-2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes, Obesity & Metabolism 9 (2007) 166-174
62. Rosenstock J., Brazg R.G., Andryuk P.J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type-2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics 28 (2006) 1556-1568
63. Fonseca V., Schweizer A., Albrecht D., et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50 (2007) 1148-1155
64. Mentlein R. Cell surface peptidases. International Review of Cytology 235 (2004) 165-213
65. Lankas G.R., Leiting B., Roy R.S., et al. Dipeptidyl peptidase IV inhibition for the treatment of type-2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54 (2005) 2988-2994
66. Mari A., Sallas W.M., He Y.L., et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type-2 diabetes. The Journal of Clinical Endocrinology and Metabolic 90 (2005) 4888-4894
67. Ahrén B., Pacini G., Foley J.E., et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type-2 diabetes over 1 year. Diabetes Care 28 (2005) 1936-1940
68. Balas B., Baig M.R., Watson C., et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients. The Journal of Clinical Endocrinology and Metabolism 92 (2007) 1249-1255
69. Nauck M.A., Heimesaat M.M., Behle K., et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 1239-1246
70. Azuma K., Radikova Z., Mancino J.M., et-al. DPP-4 inhibition improves insulin resistance (IR) in type 2 DM. ADA Session 2006; Late Breaking Abstract 5-LB.
71. Pospisilik J.A., Martin J., Doty T., et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52 (2003) 741-750
72. Duttaroy A., Voelker F., Zhang X., et al. The DPP-4 inhibitor vildagliptin increases β-cell mass in rodents. Diabetologia 48 Suppl 1 (2005) A178
73. Matikainen N., Mänttäri S., Schweizer A., et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type-2 diabetes. Diabetologia 49 (2006) 2049-2057
74. Kolterman O.G., Buse J.B., Fineman M.S., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type-2 diabetes. The Journal of Clinical Endocrinology and Metabolism 88 (2003) 3082-3089
75. Vella A., Bock G., Giesler P.D., et al. Effects of dipeptidyl peptidase 4 inhibition on gastrointestinal function, meal appearance and glucose metabolism in type-2 diabetes. Diabetes 56 (2007) 1475-1480